We could hypothesize that LOXL2 was overexpressed in tissues and cells of patients with gemcitabine-resistant pancreatic cancer based on confirmed results and that it would play an important role in the resistance-related mechanism. The gene discussed is LOXL2; the disease is familial pancreatic carcinoma.